Ginkgo Bioworks Holdings, Inc. (DNA) Stock Score, Valuation & Financial Research
Ginkgo Bioworks Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for DNA
Ginkgo Bioworks Holdings, Inc. currently has a Wall Street Score of 16/100. The stored market price is $7.06. Its financial score is 20/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Ginkgo Bioworks Holdings, Inc. does
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the compan
DNA financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $7.06
- Market capitalization:
- $461.2M
- Revenue:
- $111.9M
- Net income:
- $-290.8M
- Free cash flow:
- $-178.7M
- Cash:
- $84.5M
- Total debt:
- $404.1M
- EPS:
- -5.02
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 3/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-178.7M, showing cash burn in the current stored period.
- The balance sheet shows $84.5M of cash versus $404.1M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: DNA increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-06.
How to research DNA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.